Go to Contents Go to Navigation

Handok Pharmaceutical, Genexine purchase U.S. bio firm

All Headlines 14:17 January 08, 2019

SEOUL, Jan. 8 (Yonhap) -- South Korean drugmaker Handok Pharmaceuticals Co. said Tuesday that it has entered a US$25 million preferred stock purchase agreement with local player Genexine Inc. to invest in an American drugmaker.

The arrangement allows the two companies to purchase a combined 54 percent share of Rezolute Inc., a clinical stage biopharmaceutical company, officials said.

Handok Pharmaceutical said the purchase is a strategic investment as the company aims to make further inroads into the world's largest biopharmaceutical market.

"We believe the purchase will play a bigger role for Handok to make headway in the United States," CEO Kim Young-jin said in a press release.

Rezolute, established in 2010, specializes in the development of medication to fight metabolic and orphan diseases.

Handok Pharmaceuticals' corporate logo (Yonhap)

khj@yna.co.kr
(END)

Keywords
HOME TOP
Send Feedback
How can we improve?
Thanks for your feedback!